Central Diabetes Insipidus Clinical Trial
Official title:
Effects of Intranasal Oxytocin in Patients With Central Diabetes Insipidus - A Pilot Study
This is a randomized, double-blind, placebo-controlled crossover pilot study of single-dose intranasal oxytocin (4 IU and 24 IU) in 18-60-year-old men and women with central diabetes insipidus to evaluate the effect of oxytocin on anxiety, depression and socioemotional functioning. Following a screening visit to determine eligibility, participants will return for three main study visits. During the main study visits, study participants will receive either oxytocin or placebo, followed by assessments of emotional behavior. Thirty participants will be equally randomized to one of six possible drug orders: 1. 4 IU oxytocin - 24 IU oxytocin - placebo 2. 4 IU oxytocin - placebo - 24 IU oxytocin 3. 24 IU oxytocin - 4 IU oxytocin - placebo 4. 24 IU oxytocin - placebo - 4 IU oxytocin 5. placebo - 4 IU oxytocin - 24 IU oxytocin 6. placebo - 24 IU oxytocin - 4 IU oxytocin
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04897802 -
Identification and Clinical Relevance of an Oxytocin Deficient State (GLP1 Study)
|
Phase 4 | |
Recruiting |
NCT03474601 -
Seoul National University Pituitary Disease Cohort Study
|
||
Completed |
NCT04902235 -
Identification and Clinical Relevance of an Oxytocin Deficient State (CRH Study)
|
Phase 4 | |
Completed |
NCT01280188 -
A Study of Minirin Melt in Japanese Patients With Central Diabetes Insipidus (CDI).
|
Phase 3 | |
Completed |
NCT05319301 -
Identification and Clinical Relevance of an Oxytocin Deficient State (Melatonin Study)
|
N/A |